He will succeed current CSO Dr. Shankar Hariharan, who is leaving Amneal on May 24, 2019.
Pradeep brings significant R and D expertise to Amneal, including more than 20 years leading the development capabilities for several leading generic and specialty pharmaceutical companies.
Throughout his career, his leadership has resulted in the development and filing of more than 200 products, including numerous first-to-file and first-to-market opportunities.
Pradeep joins Amneal from Apotex, Inc., where he most recently served as executive vice president, Global R and D, responsible for leading the company's entire global R and D activities.
He also managed a large generic R and D portfolio across many dosage forms for various global markets.
Prior to joining Apotex, he served as vice president - Generic R and D for Allergan/Actavis.
Pradeep holds a Master of Pharmacy (M.Pharm) from the Birla Institute of Technology in India and a Bachelor of Pharmacy from SGSITS, Devi Ahilya University in India. He also holds several patents and has published research in various publications.
Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in Bridgewater, NJ, is an integrated pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products.
The company has approximately 6,500 employees in its operations in North America, Asia, and Europe, working together to bring high-quality medicines to patients primarily within the United States.
Amneal is one of the largest and fastest growing generic pharmaceutical manufacturers in the United States, with an expanding portfolio of generic products to include complex dosage forms in a broad range of therapeutic areas.
The company also markets a portfolio of branded pharmaceutical products through its Specialty Pharma division focused principally on central nervous system disorders and parasitic infections.
Par Health launches generic version of Janumet XR tablets in US
EQL Pharma gains approval to sell Mellozzan in Kazakhstan
Newbury Pharmaceuticals receives Swedish approval for generic tofacitinib
Breckenridge launches Tofacitinib Tablets, generic equivalent to Pfizer's Xeljanz
Hims & Hers expands GLP-1 offering in Canada with generic semaglutide
Apotex announces commercial launch of Apo-Semaglutide Injection in Canada
Transpire Bio's generic high-strength Trelegy Ellipta ANDA accepted for filing by US FDA
Kaiser Permanente reports study findings showing significant cost savings
Apotex receives Health Canada approval for a generic Ozempic equivalent
Cipla's AB-rated Ventolin HFA generic receives US FDA approval
Newbury Pharmaceuticals secures first Scandinavian approval for palbociclib generic
Apotex's generic Ozempic (Semaglutide Injection) receives US FDA tentative approval
DifGen and Apotex report FDA approval of generic Nintedanib Soft Gel Capsules